For example, TP53 mutation rates vary from 2.2% in renal cell carcinoma to 89% and 94.9% in endometrial carcinoma and serous ovarian cancers, respectively.13 Inherited TP53 mutations lead to a wide spectrum of early-onset cancers.14 In contrast to other tumour-suppressor genes that are mainly altered by truncating mutations, the majority of TP53 mutations are missense substitutions (75%). This evidence concerns the gene TP53 and cancer.